Serplulimab plus chemotherapy vs chemotherapy for treatment of US and Chinese patients with extensive-stage small-cell lung cancer: a cost-effectiveness analysis to inform drug pricing

Taihang Shao^1*, Mingye Zhao^1*, Leyi Liang¹, Wenxi Tang^1,2#

1 Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, China, 211198
2 Department of Public Affairs Management, School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China, 211198

*These authors contributed equally to this work;
#Corresponding authors

PS: Codes in this repository are used to reproduce this analysis.
Original data are also provided in this repository.

Journal: BioDrugs
DOI: https://doi.org/10.1007/s40259-023-00586-6

Any questions or technical consulting:
Email: cpu_sth@stu.cpu.edu.cn
Please do not directly send us the data and ask us to modify the codes for you. And please do not ask us the questions related to the basic usage of R or Winbugs. We highly recommend you to have a try by yourselves so that you can master these methods. If you still have difficulties in using these codes after several tries, you could choose to tell us your problems and we will try best to answer.

A copy of this article can be obtained through the following QR code

Supplementary material can be obtained through the following URL:

https://link.springer.com/article/10.1007/s40259-023-00586-6#Sec22